Cell Therapy Archives | Page 26 of 62

AABB Introduces New Cell and Gene Therapy Standards for Pharmacy

October 30, 2024 By Cade Hildreth, Founder & President Leave a Comment

Oct 16, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to introduce the proposed first edition of Cell and Gene Therapy Standards for Pharmacy, available for public comment through Dec. 16. These new standards represent an important advancement in ensuring the highest level of quality and safety for cell and gene therapy (CGT) products.

As more and more CGTs gain approval, pharmacies are becoming key players in managing these complex, high-value therapies. A review of existing pharmacy quality programs and available certifications revealed a lack of standards for handling and managing CGTs within pharmacy. [Read more…]

Nucleus Biologics Launches NB-KUL™ DF: A DMSO-Free, Chemically-Defined Cryomedia Revolutionizing Cell and Gene Therapy Cryopreservation

October 17, 2024 By Cade Hildreth, Founder & President Leave a Comment

San Diego, CA, October 15, 2024 – Nucleus Biologics, a leading provider of cell culture and bioprocessing solutions for the cell and gene therapy (CGT) industry, has launched NB-KUL DF, a DMSO-free, chemically-defined cryomedia set to redefine cryopreservation standards. Designed for CGT manufacturers, NB-KUL DF matches DMSO-based media performance and outperforms other DMSO-free options in cell viability, recovery, and expansion. While DMSO is an effective cryoprotectant, its toxicity compromises cell viability, can cause patient issues, and requires complex wash steps, adding cost and variability. NB-KUL DF eliminates these issues, offering a DMSO-free solution that preserves cell integrity, eliminates the potential for patient side effects, and simplifies cryopreservation making it ideal for T cells, MSCs, and other sensitive cell types used in CGT. [Read more…]

AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program

October 16, 2024 By Cade Hildreth, Founder & President Leave a Comment

Oct 11, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include:

• CABP Exam Prep Bootcamps Video Series [Read more…]

ARCH Venture Fund XIII Secures a Staggering $3 Billion to Support Early-Stage Biotech Companies

September 29, 2024 By Cade Hildreth, Founder & President Leave a Comment

On September 26th, 2024, ARCH Venture Partners announced it had closed ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the launch and growth of early-stage biotech companies. This latest fund builds on ARCH’s longstanding goal of investing in transformative healthcare solutions, with a focus on advanced therapies, AI, and other cutting-edge solutions. [Read more…]

iPSC Market Leaders and their Business Models

August 20, 2024 By Cade Hildreth, Founder & President 2 Comments

Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. [Read more…]